News
From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...
9h
Raw Story on MSN'A plant!' Far-right turns on MAGA mega influencer after major ousterA far-right influencer close to President Donald Trump faces suspicion from some of her fellow conspiracy theorists, who ...
After Loomer targeted surgeon general nominee and Kennedy ally Casey Means, Means’s brother, Calley, suggested that Loomer’s ...
President Trump's executive order to "identify and take appropriate action to correct past misconduct by the Federal Government related to censorship of protected speech" is good enough, DOJ tells ...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the ...
Vinay Prasad, a professor who until earlier this year headed a cancer-drugs and health-policy lab at UC San Francisco, ...
Vinay Prasad's interim replacement has concerns about same drug that drove him out. NIH director says employee critics ...
Wall Street had a slew of upgrades and downgrades from analysts. Here are some of the major calls for the week: J.P. Morgan ...
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
This week on "The Readout LOUD," STAT's biotech reporters parse what Vinay Prasad's ouster means for biotech and the FDA.
More deals are likely coming down the pipeline for Biogen Inc. as the company looks to build out its early-stage pipeline.
The U.S. Food and Drug Administration's (FDA) top vaccine official is stepping down after just three months in a role that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results